#USA #ILC Dover #Lillington #GLP-1 therapies #Water for Injection

ILC Dover Expands Life Sciences Presence with Advanced Water for Injection Solutions

ILC Dover, a leading company in the innovative design and production for various high-demand industries including biopharmaceutical and medical devices, has made a significant move to strengthen its life sciences capabilities. Recently, the company announced the introduction of Water for Injection (WFI) and custom chemical solutions, marking a remarkable expansion within their operations.

Located in Lillington, North Carolina, this expansion is aimed at augmenting ILC Dover’s contributions to the pharmaceutical sector, particularly in the production of injectable therapies and other high-purity applications requiring stringent quality standards. WFI is recognized as a crucial component in pharmaceutical manufacturing, facilitating the creation of various injectable treatments that must adhere to absolute quality standards.

In addition to WFI, ILC Dover is ramping up its provision of high-purity, cGMP-aligned contract formulation and filling services. This bolstered service portfolio is designed to cater not only to the pharmaceutical and biopharmaceutical sectors but also to makers of regulated medical devices and diagnostics.

Ciro Ahumada, the Vice President and General Manager of Biopharma Pharmaceuticals at Ingersoll Rand, emphasizes the significance of this development. He noted, "Life sciences innovation depends on absolute quality, reliability, and compliance. By integrating WFI and custom chemical solutions into our product line, we enhance our capability to assist our clients throughout every stage of drug development and production."

Supporting Continuous Growth in Life Sciences and GLP-1 Therapies

ILC Dover has established a solid reputation in the life sciences arena, particularly in driving advancements in aseptic processing and containment technology. With the addition of WFI capabilities, the company is now more equipped than ever to support the escalating demand for injectable therapies, particularly in the burgeoning area of GLP-1 treatments.

The rising global demand for GLP-1 therapies has transformed this sector, compelling manufacturers to scale operations while ensuring efficiency and regulatory compliance. To meet these growing demands, ILC Dover is introducing specialized solutions tailored to GLP-1 manufacturing, incorporating new WFI capabilities alongside contract formulation and filling services to uphold high standards for safety and sterility.

A Landmark Expansion in Lillington, North Carolina

On April 15th, 2026, ILC Dover celebrated the grand opening of a new 65,000 square-foot life sciences manufacturing facility in Lillington, marking a transformative milestone for both the organization and the local community. Visitors to the facility were welcomed to tour the space, highlighting its three ISO 7 Cleanrooms designed for controlled production environments along with ISO 13485 certification and FDA registration, showcasing its commitment to quality and compliance.

The ribbon-cutting ceremony underscored ILC Dover’s investment in advanced manufacturing and innovation, emphasizing overall regional growth. During the event, both employees and community members gathered in celebration of the new facility, which positions ILC Dover for a more integral role within the life sciences sector.

This facility enables ILC Dover to supply high-purity, cGMP-compliant non-API liquid manufacturing services. They are also well-equipped in custom formulation development and aseptic filling, providing flexible bag or bottle packaging solutions that accommodate scalable batch sizes, transitioning seamlessly from development through to commercial production. The new site incorporates comprehensive analytical testing and validation capabilities, rounding out ILC Dover’s robust quality assurance systems, including ISO 9001 and ISO 13485 certifications, further cementing their status as a reliable partner in liquid manufacturing and fulfillment for life sciences.

For those interested in discovering more about ILC Dover’s WFI offerings or considering their CDMO services, further information is accessible through their website.

In conclusion, with the unveiling of this state-of-the-art facility and the expansion of service capabilities, ILC Dover remains dedicated to addressing the complexities within life sciences, ultimately enabling the continuous rollout of life-saving therapies.

For press inquiries, please contact Stephanie Arthurs, Marketing Manager – BioPharma at [email protected]